MX355670B - Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio. - Google Patents

Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio.

Info

Publication number
MX355670B
MX355670B MX2014010139A MX2014010139A MX355670B MX 355670 B MX355670 B MX 355670B MX 2014010139 A MX2014010139 A MX 2014010139A MX 2014010139 A MX2014010139 A MX 2014010139A MX 355670 B MX355670 B MX 355670B
Authority
MX
Mexico
Prior art keywords
calcium sensitive
sensitive receiver
casr
compounds replaced
chrome compounds
Prior art date
Application number
MX2014010139A
Other languages
English (en)
Spanish (es)
Other versions
MX2014010139A (es
Inventor
Gangaram Sarde Ankush
Kumar Kamboj Rajender
Ramprasad Shukla Manojkumar
Maganlal Loriya Rajeshkumar
Dilip Pachpute Vipul
Bajirao Walke Navnath
Anant Kulkarni Sanjeev
P Palle Venkata
Hussain Khan Talha
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2014010139A publication Critical patent/MX2014010139A/es
Publication of MX355670B publication Critical patent/MX355670B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
MX2014010139A 2012-02-24 2013-02-22 Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio. MX355670B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN178KO2012 2012-02-24
IN1030KO2012 2012-09-07
PCT/IB2013/051445 WO2013124828A1 (en) 2012-02-24 2013-02-22 Substituted chroman compounds as calcium sensing receptor modulators

Publications (2)

Publication Number Publication Date
MX2014010139A MX2014010139A (es) 2015-09-04
MX355670B true MX355670B (es) 2018-04-25

Family

ID=54261188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010139A MX355670B (es) 2012-02-24 2013-02-22 Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio.

Country Status (44)

Country Link
US (3) US9163001B2 (enExample)
EP (1) EP2817299B1 (enExample)
JP (1) JP6114316B2 (enExample)
KR (1) KR102041154B1 (enExample)
CN (1) CN104350047B (enExample)
AP (1) AP2014007919A0 (enExample)
AR (1) AR090135A1 (enExample)
AU (1) AU2013223715B2 (enExample)
BR (1) BR112014021133B1 (enExample)
CA (1) CA2864332C (enExample)
CL (1) CL2014002218A1 (enExample)
CO (1) CO7160018A2 (enExample)
CR (1) CR20140424A (enExample)
CU (1) CU24325B1 (enExample)
CY (1) CY1122017T1 (enExample)
DK (1) DK2817299T3 (enExample)
DO (1) DOP2014000193A (enExample)
EA (1) EA026940B9 (enExample)
ES (1) ES2743492T3 (enExample)
GE (1) GEP20186911B (enExample)
GT (1) GT201400179A (enExample)
HR (1) HRP20191606T1 (enExample)
HU (1) HUE046172T2 (enExample)
IL (1) IL234252A (enExample)
IN (1) IN2014MN01672A (enExample)
LT (1) LT2817299T (enExample)
MA (1) MA35937B1 (enExample)
MX (1) MX355670B (enExample)
MY (1) MY171374A (enExample)
NI (1) NI201400094A (enExample)
NZ (1) NZ628627A (enExample)
PE (1) PE20142281A1 (enExample)
PH (1) PH12014501891B1 (enExample)
PL (1) PL2817299T3 (enExample)
PT (1) PT2817299T (enExample)
RS (1) RS59172B1 (enExample)
SG (1) SG11201405117SA (enExample)
SI (1) SI2817299T1 (enExample)
SM (1) SMT201900506T1 (enExample)
TN (1) TN2014000352A1 (enExample)
TW (1) TWI617549B (enExample)
UA (1) UA112679C2 (enExample)
WO (1) WO2013124828A1 (enExample)
ZA (1) ZA201405990B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24325B1 (es) * 2012-02-24 2018-03-13 Lupin Atlantis Holdings Sa Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores
WO2014033604A1 (en) * 2012-08-27 2014-03-06 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
CA2920818A1 (en) 2013-08-28 2015-03-05 Lupin Limited Substituted naphthalene compounds as calcium sensing receptor modulators
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
BR112022009649A2 (pt) 2019-11-19 2022-08-16 Lupin Ltd Processo, intermediários e métodos para preparar compostos de cromano
BR112022012663A2 (pt) * 2019-12-27 2022-09-06 Lupin Ltd Composição farmacêutica de moduladores de casr e métodos e usos da mesma
FI4090654T3 (fi) 2020-01-17 2025-09-30 Lupin Ltd Menetelmiä, prosesseja ja välituotteita kromaaniyhdisteiden valmistamiseksi

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3063585D1 (en) * 1979-05-19 1983-07-07 Beecham Group Plc Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them
US5387587A (en) * 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
JPWO2004106280A1 (ja) 2003-05-28 2006-07-20 日本たばこ産業株式会社 CaSRアンタゴニスト
US7585886B2 (en) 2005-05-19 2009-09-08 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
TW200815388A (en) 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
WO2008041118A2 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008057282A1 (en) * 2006-10-26 2008-05-15 Amgen Inc. Calcium receptor modulating agents
JPWO2008059854A1 (ja) 2006-11-16 2010-03-04 アステラス製薬株式会社 ピペリジン誘導体またはその塩
CA2701792A1 (en) * 2007-10-15 2009-04-23 Amgen Inc. Calcium receptor modulating agents
CA2706076A1 (en) 2007-11-23 2009-05-28 Leo Pharma A/S Novel cyclic hydrocarbon compounds for the treatment of diseases
CN103980309B (zh) 2008-10-03 2016-04-06 味之素株式会社 CaSR激动剂
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
EP2435404A1 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体
CN103228629A (zh) 2010-11-26 2013-07-31 利奥制药有限公司 作为CaSR活性化合物的被取代的环戊基-氮杂苯类
RU2013128973A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
WO2012069419A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
WO2012120476A1 (en) 2011-03-10 2012-09-13 Lupin Limited Substituted morpholines as modulators for the calcium sensing receptor
WO2012127388A1 (en) 2011-03-18 2012-09-27 Lupin Limited Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
CU24325B1 (es) * 2012-02-24 2018-03-13 Lupin Atlantis Holdings Sa Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores

Also Published As

Publication number Publication date
CA2864332C (en) 2020-08-25
SMT201900506T1 (it) 2019-11-13
SG11201405117SA (en) 2014-09-26
EA201491582A1 (ru) 2014-12-30
HUE046172T2 (hu) 2020-02-28
CR20140424A (es) 2015-01-13
JP2015508097A (ja) 2015-03-16
AR090135A1 (es) 2014-10-22
PH12014501891A1 (en) 2015-02-09
CU24325B1 (es) 2018-03-13
AP2014007919A0 (en) 2014-09-30
BR112014021133B1 (pt) 2022-06-28
IN2014MN01672A (enExample) 2015-05-29
WO2013124828A1 (en) 2013-08-29
CA2864332A1 (en) 2013-08-29
MX2014010139A (es) 2015-09-04
EA026940B1 (ru) 2017-06-30
UA112679C2 (uk) 2016-10-10
US20170209410A1 (en) 2017-07-27
AU2013223715B2 (en) 2017-09-14
CY1122017T1 (el) 2020-10-14
ES2743492T3 (es) 2020-02-19
EP2817299B1 (en) 2019-06-12
EA026940B9 (ru) 2017-11-30
DOP2014000193A (es) 2017-01-15
KR102041154B1 (ko) 2019-11-07
US9598391B2 (en) 2017-03-21
DK2817299T3 (da) 2019-09-16
HK1205117A1 (en) 2015-12-11
BR112014021133A2 (pt) 2018-09-11
ZA201405990B (en) 2015-11-25
PL2817299T3 (pl) 2019-12-31
LT2817299T (lt) 2019-09-25
MY171374A (en) 2019-10-10
CL2014002218A1 (es) 2015-03-06
HRP20191606T1 (hr) 2019-12-13
GT201400179A (es) 2016-03-01
CN104350047B (zh) 2017-05-24
RS59172B1 (sr) 2019-10-31
PH12014501891B1 (en) 2021-05-05
KR20140135731A (ko) 2014-11-26
MA35937B1 (fr) 2014-12-01
TWI617549B (zh) 2018-03-11
TW201336831A (zh) 2013-09-16
IL234252A (en) 2017-02-28
CO7160018A2 (es) 2015-01-15
NZ628627A (en) 2017-02-24
US20150038546A1 (en) 2015-02-05
JP6114316B2 (ja) 2017-04-12
NI201400094A (es) 2015-03-27
TN2014000352A1 (en) 2015-12-21
US9163001B2 (en) 2015-10-20
PT2817299T (pt) 2019-09-23
CN104350047A (zh) 2015-02-11
GEP20186911B (en) 2018-10-25
US9987249B2 (en) 2018-06-05
SI2817299T1 (sl) 2019-10-30
US20150368222A1 (en) 2015-12-24
EP2817299A1 (en) 2014-12-31
CU20140103A7 (es) 2015-01-29
AU2013223715A1 (en) 2014-08-28
PE20142281A1 (es) 2015-01-16

Similar Documents

Publication Publication Date Title
MX355670B (es) Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio.
GT201400102A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
MX336549B (es) Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1.
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
UY32574A (es) Antagonistas del receptor cxcr3
CR20110455A (es) Derivados de indol como antagonistas del receptor crth2
CO2017006174A2 (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis
PH12013501899A1 (en) Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
CR20150425A (es) Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes
CL2017000818A1 (es) Derivativos de benzotiofenil substituidos como agonistas gpr40 para el tratamiento de diabetes tipo ii
ECSP13012800A (es) Dihidrofuranos condensados en calidad de moduladores de gpr119 para el tratamiento de diabetes, obesidad y trastornos relacionados.
CR20150084A (es) 2-oxo-2,3-dihidro-indoles
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
CR20150144A (es) Derivados de etinilo como moduladores del receptor de actividad mglur5
MX385858B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
UY36209A (es) Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen
UY31951A (es) Proceso para la preparación de derivados de benzoimidazol-2-ilpirimidina
MX2014014751A (es) Compuestos de heteroarilo y metodos de uso de los mismos.
UY33230A (es) Aminotiazolonas como moduladores del receptor alfa relacionados con estrógeno
IN2015MN00421A (enExample)
CR20150068A (es) Ciclopentilpirazoles como bloqueadores del canal de calcio tipo n
UY34489A (es) Derivados del ácido cicloalcanocarboxílico como antagonistas del receptor CXCR3
UY34819A (es) Derivados de ß-aminoácido sustituidos como antagonistas del receptor CXCR3.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: LUPIN ATLANTIS HOLDINGS SA

FG Grant or registration